Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jonathan Stutters
Observed names:
J. Stutters,
Jon Stutters,
Stutters J.,
Stutters, J,
Stutters, Jon,
Stutters, Jonathan
show all 6
Institutions:
National Hospital for Neurology and Neurosurgery,
UCL Queen Square Institute of Neurology,
University College London,
Universitat de Barcelona
Observed institutions:
National Hospital for Neurology and Neurosurgery,
UCL Queen Square Institute of Neurology,
University College London,
Universitat de Barcelona
ORCID:
0000-0002-9151-0844
Observed ORCID:
0000-0002-9151-0844
OpenAlex ID:
A5027448340
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
2020
·
Jeremy Chataway
, Floriana De Angelis
, et al.
·
The Lancet Neurology
·
142
PDF
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
2021
·
J William L Brown
, Nick G Cunniffe
, et al.
·
The Lancet Neurology
·
113
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
2021
·
Hans-Peter Hartung
, Tobias Derfuss
, et al.
·
Multiple Sclerosis Journal
·
97
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis
2022
·
Alberto Calvi
, Ferran Prados Carrasco
, et al.
·
Neurology
·
90
Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis
2022
·
Alberto Calvi
, Carmen Tur
, et al.
·
NeuroImage Clinical
·
68
PDF
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
2018
·
Peter Connick
, Floriana De Angelis
, et al.
·
BMJ Open
·
62
PDF
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
2021
·
Elisa Colato
, Jonathan Stutters
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
53
PDF
Functional specialization and generalization for grouping of stimuli based on colour and motion
2013
·
Semir Zeki
, Jonathan Stutters
·
NeuroImage
·
34
A brain-derived metric for preferred kinetic stimuli
2012
·
Semir Zeki
, Jonathan Stutters
·
Open Biology
·
33
Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research
2025
·
Philipp Goebl
, Jed Wingrove
, et al.
·
Nature Communications
·
29
PDF
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
2020
·
Floriana De Angelis
, Peter Connick
, et al.
·
Efficacy and Mechanism Evaluation
·
28
PDF
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
2022
·
J. William L. Brown
, Ferran Prados
, et al.
·
Annals of Clinical and Translational Neurology
·
27
PDF
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial
2025
·
Jeremy Chataway
, Thomas Williams
, et al.
·
The Lancet
·
24
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study
2020
·
B.S. Solanky
, N.A. John
, et al.
·
American Journal of Neuroradiology
·
18
PDF
Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis
2023
·
Alberto Calvi
, Zoe Mendelsohn
, et al.
·
European Journal of Neurology
·
16
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments
2023
·
Nevin A. John
, Bhavana S. Solanky
, et al.
·
Journal of Magnetic Resonance Imaging
·
16
PDF
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis from the MS‐STAT2 randomized controlled trial
2023
·
Thomas Williams
, Nevin John
, et al.
·
European Journal of Neurology
·
14
PDF
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial
2024
·
Floriana De Angelis
, James R Cameron
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
9
PDF
Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS)
2015
·
Yaldizli, O
, MacManus, D
, et al.
·
UCL Discovery (University College London)
·
9
Networks of microstructural damage predict disability in multiple sclerosis
2023
·
Elisa Colato
, Ferran Prados
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
7
Neurofilament heavy chain in secondary progressive multiple sclerosis
2025
·
Floriana De Angelis
, Francesca Ammoscato
, et al.
·
Multiple Sclerosis Journal
·
5
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis
2024
·
Nevin A. John
, Yingtong Li
, et al.
·
European Journal of Neurology
·
5
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial
2024
·
Thomas Williams
, Nevin John
, et al.
·
Neuroimage Reports
·
4
Brain reserve and physical disability in secondary progressive multiple sclerosis
2024
·
Nevin John
, Yingtong Li
, et al.
·
BMJ Neurology Open
·
4
PDF
Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosis
2024
·
Elisa Colato
, Jonathan Stutters
, et al.
·
Brain Communications
·
3
Show more works
View as search
Works count:
50
Citation count:
933
H-index:
16
I10-index:
18
Year
Topic
Type